Latest From Exscientia Ltd.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
- Drug Discovery Tools
- Digital Health
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Exscientia Ltd.
- Senior Management
Andrew Hopkins, CEO
Georgy Egorov, CFO
Mark Swindells, PhD, COO
Jeremy Besnard, PhD, Chief Designer
Richard Bickerton, PhD, CIO
Andy Bell, PhD, Chief Research officer
Richard Cox, MSc, Dir, Engineering
Adrian Schreyer, PhD, CTO
Heather Togwell, Ops Manager
- Contact Info
Dundee Incubator, James Lindsay Place
Dundee, DD1 5JJ
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.